Skip to Main Content

INFORMATION FOR

    Demetrios Braddock, MD, PhD

    Associate Professor of Pathology
    DownloadHi-Res Photo

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    About

    Titles

    Associate Professor of Pathology

    Biography

    Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004 where he practices hematopathology and heads a laboratory studying pathogenic mechanisms of severe and poorly addressed human diseases. His laboratory focuses on rare diseases of children, and on the design and engineering of novel biologics to modulate disease outcomes.

    Dr. Braddock’s laboratory has designed and validated an enzyme biologic for a lethal infantile calcification disorder called ‘Generalized Arterial Calcification of Infancy’ (GACI), which has been translated into infants, children, and adults with GACI, ARHR2, PXE, and CKD-MBD (ClinicalTrials.gov: NCT05734196, NCT06046820, NCT04686175, NCT06283589).

    Appointments

    • Pathology

      Associate Professor on Term
      Primary

    Other Departments & Organizations

    Education & Training

    Fellow
    Yale University School of Medicine (2010)
    Resident
    National Cancer Institute, NIH, Laboratory of Pathology (2000)
    MD
    University of Chicago Pritzker School of Medicine (1996)
    PhD
    University of Chicago (1994)

    Research

    Overview

    My group is primarily interested in biochemical and structural pathogenesis of blood disorders and protein engineering, and have focused our work on understanding the physiologic role of the ENPP family of enzymes. We recently described two members of the ENPP family in brain vasculature that promote platelet aggregation and calcification. Polymorphisms in one of these enzymes (ENPP1) was recently described to confer stroke protection to pediatric sickle cell patients and a lethal neonatal vascular calcification disorder called 'Generalized Arterial Calcification of Infancy' (GACI). Insights into this pathway allowed us to engineer a curative recombinant biologic which corrects disease sequela in GACI, which are moving into patients in collaboration with a company we founded (Inozyme Pharma). We have also identified a form of early onset osteoporosis associated with ENPP1 deficiency, and are investigating the role of ENPP1 in low bone mass and increased tissue calcification, a medical condition called 'Paradoxical Mineralization' which occurs in the general medical population in conditions such as aging and chronic kidney disease. We have recently expanded our research into enzyme biologics as therapeutics for oncology and autoimmune indications.

    Medical Research Interests

    Calcification, Physiologic; Osteoarthropathy, Primary Hypertrophic; Pathology; Pseudoxanthoma Elasticum; Rare Diseases; Sickle Cell Trait; Vascular Calcification

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Demetrios Braddock's published research.

    Publications

    Featured Publications

    2024

    2023

    Academic Achievements & Community Involvement

    • activity

      Scientific Advisory Board

    • honor

      Yale 2022 Faculty Innovation Award

    Clinical Care

    Overview

    Demetrios Braddock, MD, PhD, is a pathologist who specializes in diagnosing blood cancers and diseases, especially a rare disease called generalized arterial calcification of infancy (GACI). As an undergraduate student, Dr. Braddock discovered that he enjoyed the creativity of research, in addition to possibility of helping patients. He decided to pursue a PhD during his medical training. “I enjoy working at the interface of what we know and don’t know, and expanding that border to advance medicine,” he says.

    Since coming to Yale, Dr. Braddock has led research in his laboratory on a particular molecule called the ENPP enzyme. Enzymes, produced by cells in the body, serve as catalysts for different biological functions. The family of ENPP enzymes in particular help with blood vessel development and bone mineralization. Patients suffering from GACI usually have calcium deposits built up within their blood vessels, which interfere with blood flow. Dr. Braddock has developed biologic drugs that serve as enzyme replacement therapies to address rare diseases. “I will get phone calls from physicians all over who want more information about diagnosing GACI and who want to learn more about it,” he says.

    For him, patient care is one of the most significant motivators in his research lab and in the clinic, when he is examining a patient sample for evidence of disease. “The physician cannot begin treatment of a patient without the correct diagnosis,” he says. “That’s where we come in and try to get the accurate clinical diagnosis for what we see microscopically.”

    At Yale School of Medicine, Dr. Braddock is an associate professor of pathology.

    Clinical Specialties

    Pathology; Hematopathology

    Board Certifications

    • Hematology (Pathology)

      Certification Organization
      AB of Pathology
      Original Certification Date
      2012
    • Anatomic Pathology

      Certification Organization
      AB of Pathology
      Original Certification Date
      2000

    Get In Touch

    Contacts

    Academic Office Number
    Clinical Inquiry Number
    Lab Number
    Office Fax Number

    Administrative Support

    Locations